• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » St. Jude making progress in neuromodulation market

St. Jude making progress in neuromodulation market

December 3, 2010 By MedCity News

MedCity News logo

St. Jude Medical Inc. (NYSE:STJ) reintroduced physicians at the North American Neuromodulation Society meeting in Las Vegas to its Penta surgical lead for neurostimulation therapy.

Since last year’s society meeting, during which St. Jude announced Food & Drug Administration clearance to sell the device in the United States, St. Jude has received CE Mark approval to sell the device in Europe and reimbursement approval from the Australian Therapeutic Goods Administration.

The Little Canada, Minn.-based medical device maker bills the five-column surgical lead as the first of its kind, having the smallest electrodes on the market. Because of its design and ability to deliver more electricity through smaller electrodes, the device may enable doctors to better manage patients’ chronic back pain after surgery has failed, the company said in a written statement.

“Early adoption of the Penta lead in the [U.S.] has been very promising, and we are encouraged by how well this paddle lead is aiding physicians in controlling low back pain,” Chris Chavez, president of the St. Jude’s Neuromodulation Division, in the statement. “We are excited to be able to make this first-of-its-kind product available to physicians in Europe and Australia.”

Known mostly for its pacemakers and implantable cardio defibrillators, St. Jude got into the neurostimulation business in a big way in 2005 when it purchased Advanced Neuromodulation Systems in Plano, Texas. The smooth acquisition gave the device maker a much-needed boost in revenue at a time when global demand for mechanical heart devices started to wane.

ANS also has helped St. Jude narrow the considerable lead of Fridley, Minn.-based neurostimulation industry competitor Medtronic Inc. (NYSE:MDT). Last year, St. Jude won European approval for its Libra deep brain stimulation device to treat Parkinson’s disease. It hopes to challenge Medtronic’s Activa devices in the United States. St. Jude is conducting clinical trials on a deep brain stimulation device to treat depression. And the company recently entered China and Japan.

Filed Under: Business/Financial News, Neuromodulation/Neurostimulation, News Well Tagged With: stjudemedical

More recent news

  • Aurora Spine begins first procedures with Aero lumbar fusion system
  • Caranx Medical surgical robot TaviPilot AI software wins FDA clearance
  • InspireMD launches carotid stent in U.S. after FDA approval
  • Neuros Medical raises $56M Series D to support nerve stim tech
  • CorWave reports first-in-human LVAD implant

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy